IP Library Granted Patent US 8,742,113
Granted Patent B2
US 8,742,113 · App. 14/008,488 · Granted Jun 3, 2014

Furanone derivative

Inventors: Takayuki Irie (Kobe, JP); Ayako Sawa (Osaka, JP); Masaaki Sawa (Ibaraki, JP); Tokiko Asami (Kobe, JP); Yoko Funakoshi (Tokyo, JP); Chika Tanaka (Tokyo, JP)
Assignees: SBI Biotech Co., Ltd.; Carna Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,742,113
App. No.
14/008,488
Granted
Jun 3, 2014
Kind
B2
Abstract

To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I): wherein A represents —COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic fused ring, or an optionally substituted amino group; or alternatively, R2 and R3, taken together with the nitrogen atom to which they are attached, may form an optionally substituted heterocycle or an optionally substituted heterocyclic fused ring; and R4 represents a hydrogen atom or a halogen atom; with the proviso that when A represents —COOR1, R2 and R3 are not optionally substituted amino groups at the same time, and when A represents a hydrogen atom, R3 represents a hydrogen atom.

Claims (5)

1. A furanone derivative or a pharmaceutically acceptable salt thereof, represented by the formula (I):

[Chemical Formula 1]

wherein A represents —COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic fused ring, or an optionally substituted amino group; or alternatively, R2 and R3, taken together with the nitrogen atom to which they are attached, may form an optionally substituted heterocycle or an optionally substituted heterocyclic fused ring; and R4 represents a hydrogen atom or a halogen atom; with the proviso that when A represents —COOR1, R2 and R3 are not optionally substituted amino groups at the same time, and when A represents a hydrogen atom, R3 represents a hydrogen atom.

2. The furanone derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein A is —COOR1.

3. The furanone derivative or a pharmaceutically acceptable salt thereof according to claim 1 , wherein A is a hydrogen atom.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2016
From: SBI BIOTECH CO., LTD.
To: CARNA BIOSCIENCES, INC.
Reel/Frame 040292/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2014
From: SBI BIOTECH CO., LTD.
To: SBI BIOTECH CO., LTD.
Reel/Frame 033281/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2013
From: IRIE, TAKAYUKI; SAWA, AYAKO; SAWA, MASAAKI; ASAMI, TOKIKO; FUNAKOSHI, YOKO; TANAKA, CHIKA
To: SBI BIOTECH CO., LTD.; CARNA BIOSCIENCES, INC.
Reel/Frame 031317/0938 →
Priority Claims (1)
JP 2011-080185 · Mar 31, 2011 · national
Continuity (1)
Related Publication 20140018533A1 · Jan 16, 2014